Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 80
- Registration Number
- NCT00003732
- Locations
- 🇩🇰
Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Academisch Ziekenhuis Maastricht
- Target Recruit Count
- 140
- Registration Number
- NCT00003558
- Locations
- 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱Academisch Ziekenhuis Maastricht, Maastricht, Netherlands
Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Cancer Research Campaign Clinical Trials Centre
- Registration Number
- NCT00039546
- Locations
- 🇬🇧
Glan Clywd District General Hospital, Rhyl, Denbighshire, United Kingdom
🇬🇧Morriston Hospital NHS Trust, West Glamorgen, United Kingdom
🇬🇧Singleton Hospital, Swansea, United Kingdom
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Aventis Pharmaceuticals
- Registration Number
- NCT00002662
- Locations
- 🇺🇸
George Washington University Medical Center, Washington, District of Columbia, United States
🇺🇸Baptist Regional Cancer Institute - Jacksonville, Jacksonville, Florida, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT00003111
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Paclitaxel in Treating Older Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 120
- Registration Number
- NCT00003092
- Locations
- 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
🇺🇸CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 819
- Registration Number
- NCT00028743
- Locations
- 🇨🇦
Lions Gate Hospital, North Vancouver, British Columbia, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Radiation Therapy Oncology Group
- Registration Number
- NCT00003862
- Locations
- 🇺🇸
McLaren Regional Cancer Center, Flint, Michigan, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 3871
- Registration Number
- NCT00041119
- Locations
- 🇺🇸
UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
🇺🇸Dubs Cancer Center at Rogue Valley Medical Center, Medford, Oregon, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 65
- Registration Number
- NCT00033696
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.